Cardiovasc Diabetol February 2019 PMID 30819210

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.

Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari

Download social card

Mentions

Peak: 56 in Mar 2019

across 3 sources since Feb 2019

Extended reach

213,384

potential audience

Total likes

195

Video views

4,703

Mentions per month

Feb 2019 – Aug 2023

Where it's discussed

X / Twitter61 posts
News3 articles
YouTube2 videos

AI synopsis

What people are saying

The discussions around the article include varied responses, such as users expressing the usefulness of sotagliflozin in type 1 diabetes and emphasizing the dual inhibitory mechanism. Phrases like 'TOTALMENTE RECOMENDABLE' reflect strong enthusiasm, while concerns about the exact role of SGLT-1 indicate a critical yet engaged take on the findings. Overall, the tone varies from excitement to skepticism, demonstrating a balanced conversation about the publication's potential.

AgreementModerate agreement

Most discussions express support or curiosity about the findings related to sotagliflozin, indicating a general consensus.

InterestHigh interest

Participants demonstrate a high level of interest in the implications of sotagliflozin for diabetes management, highlighting its relevance.

EngagementModerate engagement

Many users reference specific aspects of the publication, but some comments are more surface-level discussions.

ImpactHigh impact

There is a widespread belief that this research could significantly influence diabetes treatment practices.

Abstract in brief

Sotagliflozin is a dual inhibitor targeting sodium-glucose transporters SGLT2 and SGLT1, aiding in the management of type 1 and type 2 diabetes by increasing glucose excretion and reducing glucose absorption.
Clinical trials have demonstrated that sotagliflozin effectively lowers glycated hemoglobin levels, assists with weight loss, and helps manage blood pressure in adults with type 2 diabetes, and shows promise for type 1 diabetes as well.
Ongoing research is assessing sotagliflozin's influence on cardiovascular outcomes, while this review discusses the benefits and drawbacks of dual SGLT2/1 inhibition for deeper understanding of its action and potential.

Read the full abstract

All mentions

Sotagliflozin: A Dual SGLT2 and SGLT1 Inhibitor for Diabetes and Kidney Disease

Patients with diabetes are at high risk for heart failure and ischemic events. Sotagliflozin, approved for use in diabetes and chronic kidney disease, inhibits SGLT2 and SGLT1, reducing glucose absorption and…

pharmacy by asim · Jun 20, 2023 3,861 views

Sotagliflozin: Dual SGLT Inhibitor for Diabetes Management

Sotagliflozin is a dual inhibitor targeting sodium-glucose transporters SGLT2 and SGLT1. It aids in managing type 1 and type 2 diabetes through increased glucose excretion and reduced absorption. This video explores its…

pharmacy by asim · Aug 18, 2023 842 views

Viet Le DMSc PA-C FACC FAHA HF-Cert

@VietHeartPA · X

@levenj01 @hswapnil @ChristosArgyrop Ok, you got me to drop into the rabbit hole

Aug 30, 2022 · 9,799 followers View post →

@LarissaOstfeld · X

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives | Cardiovascular Diabetology | Full Text. TIL there are SGLT1 inhibitors!

Feb 23, 2021 · 208 followers View post →

Ezekiel saw the wheel.

@Ezehtim · X

$AKBA consider loading up on $LXRX Suspect that valuation will climb x 4 within the next 6 months or buyout/partnership worth billions Fairly derided at this point https://t.co/dUekNvZA9O

Nov 29, 2020 · 82 followers View post →

Sandeep Tak MD(AIIMS Delhi), FACE

@drstak70 · X

Sep 21, 2019 · 3 likes · 1,758 followers View post →

David León Jiménez

@drleonjimenez · X

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives https://t.co/fnBFxsZXGq TOTALMENTE RECOMENDABLE

Mar 17, 2019 · 1 like · 1,120 followers View post →

Ana Piera #JuntosEsMasFacil

@ana_apiecar · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 7, 2019 · 30 shares · 2,572 followers View post →

Marta Monreal

@martamonrealv · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 7, 2019 · 30 shares · 178 followers View post →

Charo Vallelado

@CharoVallelado · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 7, 2019 · 30 shares · 2,543 followers View post →

Angela Romero Zarante, MD

@ANGELARZ28 · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 6, 2019 · 30 shares · 308 followers View post →

Lorenzo Bertomeu

@ManuduManuel · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 6, 2019 · 30 shares · 3,588 followers View post →

Juan Manuel Hernandez

@JuanmaHernande · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 6, 2019 · 30 shares · 283 followers View post →

Diego Villalba Paredes

@drdiegovillalba · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 6, 2019 · 30 shares · 516 followers View post →

Alberto Moreno

@endoalb · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 6, 2019 · 30 shares · 226 followers View post →

EsterLune

@Esterlune · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 6, 2019 · 30 shares · 408 followers View post →

Foroactua

@Foroactua · X

Mar 6, 2019 · 2 likes · 1,154 followers View post →

Alicia Yepez

@YepezDra · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 6, 2019 · 30 shares · 3,121 followers View post →

grupoCTD

@CtdGrupo · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 6, 2019 · 30 shares · 529 followers View post →

Cristina Tejera

@cristinatejerap · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 6, 2019 · 30 shares · 11,471 followers View post →

Victoria Luna

@VictoriaLuna4 · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 6, 2019 · 30 shares · 1,579 followers View post →

Sandra Tapia

@mi_otrotuit · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 6, 2019 · 30 shares · 770 followers View post →

Flor García

@florblue77 · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 5, 2019 · 30 shares · 737 followers View post →

Raul Villar

@DrRaulvillar · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 5, 2019 · 30 shares · 410 followers View post →

Agelvis Martínez MD

@agelvisr · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 5, 2019 · 30 shares · 280 followers View post →

Javier Escalada #Yoelijoendocrino

@fjavesc · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 5, 2019 · 30 shares · 3,620 followers View post →

Jesus Bayort

@jesus_bayort · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 5, 2019 · 30 shares · 192 followers View post →

Elena D

@ElenaDF75 · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 5, 2019 · 30 shares · 3,904 followers View post →

Miguel Angel Oria

@OriaMiguelangel · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 5, 2019 · 30 shares · 51 followers View post →

Conchi

@ConchiNavarroH · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 5, 2019 · 30 shares · 271 followers View post →

Juanmarcosgg

@juanmarcosgg · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 5, 2019 · 30 shares · 510 followers View post →

Rosario Fernández

@RosarioFegs · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 5, 2019 · 30 shares · 396 followers View post →

Judith López

@Judithendo · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 5, 2019 · 30 shares · 1,682 followers View post →

María Riestra

@MariaRiestra_1 · X

RT @sandradurandoc: Sotaglifocina, primer inhibidor iSGLT2 dual: perspectivas actuales y futuras. Revision completa y acceso libre https://…

Mar 5, 2019 · 30 shares · 1,316 followers View post →

Alejandra Durán

@sandradurandoc · X

Mar 5, 2019 · 53 likes · 30 shares · 1,996 followers View post →

@LeDicenFido · X

RT @IlindelatorreMD: Sotagliflozin, el primer inhibidor dual de SGLT: perspectivas actuales y perspectivas | Diabetología Cardiovascular ht…

Mar 2, 2019 · 12 shares · 330 followers View post →

Agelvis Martínez MD

@agelvisr · X

RT @IlindelatorreMD: Sotagliflozin, el primer inhibidor dual de SGLT: perspectivas actuales y perspectivas | Diabetología Cardiovascular ht…

Mar 2, 2019 · 12 shares · 280 followers View post →

Christopher Sylvain

@ChrisSylvain · X

“However, the actual role played by SGLT-1 in these tissues has still not been established. Consequently, the potentially positive & negative effects of its inhibition are yet to be determined.” So why try to sell as a dual inhibitor? Just another SGLT-2i? https://t.co/Ba1vDnjUK9

Mar 2, 2019 · 589 followers View post →

Óscar Huesca

@Anaesthetist_81 · X

RT @IlindelatorreMD: Sotagliflozin, el primer inhibidor dual de SGLT: perspectivas actuales y perspectivas | Diabetología Cardiovascular ht…

Mar 2, 2019 · 12 shares · 8,387 followers View post →

Charles Odiase

@shapeurthinking · X

RT @drpatrickholmes: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Open access review. The pros and cons…

Mar 2, 2019 · 13 shares · 1,049 followers View post →

Mujer_fénix

@fenix190381 · X

RT @IlindelatorreMD: Sotagliflozin, el primer inhibidor dual de SGLT: perspectivas actuales y perspectivas | Diabetología Cardiovascular ht…

Mar 2, 2019 · 12 shares · 20 followers View post →

lapao20415724

@lapao20415724 · X

RT @IlindelatorreMD: Sotagliflozin, el primer inhibidor dual de SGLT: perspectivas actuales y perspectivas | Diabetología Cardiovascular ht…

Mar 1, 2019 · 12 shares · 89 followers View post →

Vicente Lozada-Balderrama

@VicenteLozadaB · X

RT @IlindelatorreMD: Sotagliflozin, el primer inhibidor dual de SGLT: perspectivas actuales y perspectivas | Diabetología Cardiovascular ht…

Mar 1, 2019 · 12 shares · 13,622 followers View post →

Fernando Moya-Méndez E.

@DrMoyaMendezE · X

RT @drpatrickholmes: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Open access review. The pros and cons…

Mar 1, 2019 · 13 shares · 122 followers View post →

Diego Tovar

@DiegoAlexei · X

RT @IlindelatorreMD: Sotagliflozin, el primer inhibidor dual de SGLT: perspectivas actuales y perspectivas | Diabetología Cardiovascular ht…

Mar 1, 2019 · 12 shares · 257 followers View post →

Jorge Márquez

@DrJMarquezF · X

RT @IlindelatorreMD: Sotagliflozin, el primer inhibidor dual de SGLT: perspectivas actuales y perspectivas | Diabetología Cardiovascular ht…

Mar 1, 2019 · 12 shares · 932 followers View post →

Dr. Patch Ecco, MD

@eldoc24 · X

RT @IlindelatorreMD: Sotagliflozin, el primer inhibidor dual de SGLT: perspectivas actuales y perspectivas | Diabetología Cardiovascular ht…

Mar 1, 2019 · 12 shares · 4,625 followers View post →

Eduardo Saavedra

@lemillion_ed · X

RT @IlindelatorreMD: Sotagliflozin, el primer inhibidor dual de SGLT: perspectivas actuales y perspectivas | Diabetología Cardiovascular ht…

Mar 1, 2019 · 12 shares · 327 followers View post →

Dr. cafeína

@espressso29 · X

RT @IlindelatorreMD: Sotagliflozin, el primer inhibidor dual de SGLT: perspectivas actuales y perspectivas | Diabetología Cardiovascular ht…

Mar 1, 2019 · 12 shares · 28 followers View post →

Dr. Ilin Gilberto de la Torre M.

@IlindelatorreMD · X

Sotagliflozin, el primer inhibidor dual de SGLT: perspectivas actuales y perspectivas | Diabetología Cardiovascular https://t.co/nZxex4N8Le

Mar 1, 2019 · 30 likes · 12 shares · 45,843 followers View post →

Dr. Vismay Naik

@drvismaynaik · X

RT @drpatrickholmes: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Open access review. The pros and cons…

Mar 1, 2019 · 13 shares · 459 followers View post →

Fen

@organiclemon · X

RT @drpatrickholmes: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Open access review. The pros and cons…

Mar 1, 2019 · 13 shares · 2,467 followers View post →

David France

@frandavi99 · X

RT @drpatrickholmes: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Open access review. The pros and cons…

Mar 1, 2019 · 13 shares · 1,122 followers View post →

Diabetesgeneeskunde

@DiabGeneeskunde · X

Sotagliflozine, de eerste duale SGLT remmer: wat mag er van dit middel verwacht worden? https://t.co/PaEQkkLAHD

Mar 1, 2019 · 196 followers View post →

M Shafi Kuchay

@drshafikuchay · X

RT @drpatrickholmes: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Open access review. The pros and cons…

Mar 1, 2019 · 13 shares · 19,888 followers View post →

Prof Kamlesh Khunti

@kamleshkhunti · X

RT @drpatrickholmes: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Open access review. The pros and cons…

Mar 1, 2019 · 13 shares · 24,476 followers View post →

Kevin Fernando

@drkevinfernando · X

RT @drpatrickholmes: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Open access review. The pros and cons…

Mar 1, 2019 · 13 shares · 5,138 followers View post →

Abd Tahrani

@AbdTahrani · X

RT @drpatrickholmes: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Open access review. The pros and cons…

Mar 1, 2019 · 13 shares · 7,585 followers View post →

Nicola Milne RN QN

@nicmiln · X

RT @drpatrickholmes: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Open access review. The pros and cons…

Mar 1, 2019 · 13 shares · 663 followers View post →

DSNforumUK

@DSNforumUK · X

RT @drpatrickholmes: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Open access review. The pros and cons…

Mar 1, 2019 · 13 shares · 6,376 followers View post →

Vin Woods

@vinjwoods · X

RT @drpatrickholmes: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Open access review. The pros and cons…

Mar 1, 2019 · 13 shares · 630 followers View post →

Patrick Holmes

@drpatrickholmes · X

Mar 1, 2019 · 17 likes · 13 shares · 3,353 followers View post →

tanya spencer

@tanyaspencer113 · X

#reversediabetes now ➤ https://t.co/9PTc6qwLem ♥ Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives ♥ #diabetes #diabetescure

Feb 28, 2019 · 1 like · 5 followers View post →

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Sotagliflozin: A Dual SGLT2 and SGLT1 Inhibitor for Diabetes and Kidney Disease

Sotagliflozin: Dual SGLT Inhibitor for Diabetes Management